Many de novo donor-specific antibodies recognize β2-microglobulin-free, but not intact HLA heterodimers

K. Michel1, R. Santella2, J. Steers2, A. Sahajpal1, F. X. Downey1, V. Thohan1 & M. Oaks1

1 Transplant Program, Aurora St. Luke’s Medical Center, Milwaukee, WI, USA
2 Transplant Institute, Avera McKennan Hospital and University System, Sioux Falls, SD, USA

Abstract

Solid-phase single antigen bead (SAB) assays are standard of care for detection and identification of donor-specific antibody (DSA) in patients who receive solid organ transplantation (SOT). While several studies have documented the reproducibility and sensitivity of SAB testing for DSA, there are little data available concerning its specificity. This study describes the identification of antibodies to β2-microglobulin-free human leukocyte antigen (β2-m-fHLA) heavy chains on SAB arrays and provides a reassessment of the clinical relevance of DSA testing by this platform. Post-transplant sera from 55 patients who were positive for de novo donor-specific antibodies on a SAB solid-phase immunoassay were tested under denaturing conditions in order to identify antibodies reactive with β2-m-fHLA or native HLA (nHLA). Antibodies to β2-m-fHLA were present in nearly half of patients being monitored in the post-transplant period. The frequency of antibodies to β2-m-fHLA was similar among DSA and HLA antigens that were irrelevant to the transplant (non-DSA). Among the seven patients with clinical or pathologic antibody-mediated rejection (AMR), none had antibodies to β2-m-fHLA exclusively; thus, the clinical relevance of β2-m-fHLA is unclear. Our data suggests that SAB testing produces false positive reactions due to the presence of β2-m-fHLA and these can lead to inappropriate assignment of unacceptable antigens during transplant listing and possibly inaccurate identification of DSA in the post-transplant period.

Introduction

Laboratory testing for donor-specific antibody (DSA) is a common technique to monitor immune status after solid organ transplantation (SOT). Its use as a surveillance tool complementary to the histopathologic biopsy and clinical health of the allograft has been recommended by the International Society of Heart and Lung Transplantation (ISHLT) since a consensus conference in 2008 (1). It is also recommended as a screening tool for monitoring renal transplant recipients independent of risk for AMR (2).

A major advance in human leukocyte antigen (HLA) antibody identification was the introduction of single antigen bead (SAB) arrays (3). Not long after the introduction of these assays, there were reports of the presence of alloantibodies to both HLA class I and II in nonalloimmunized males (4–6). Many of these ‘natural’ antibodies were subsequently shown to be due to peptide and β2-microglobulin-free class I heavy chain molecules present on the surface of beads (7, 8). These antibodies are reactive with epitopes accessible to binding only when the heavy chain is not associated with β2-microglobulin. In other words, β2-microglobulin-free HLA (β2-m-fHLA) antigens on the surface of the bead produce positive reactions that would otherwise not be detected on beads that consisted entirely of native HLA (nHLA). We (9) and others (10, 11) have described the frequency of these antibodies and their potential impact on organ allocation in patients awaiting cardiac and renal transplants. In general, these antibodies do not produce positive crossmatches against viable donor cells, nor do they fix complement. Anecdotal reports of transplantation across the barrier of β2-m-fHLA antibodies suggest that they may not be important to long-term graft survival (12–14). A recent study of the potential clinical relevance of pre-formed donor-specific class I antibodies to denatured HLA following renal transplantation found no increased incidence of AMR or reduced 5-year graft survival (15). Thus, the presence of the aforementioned antibodies may produce false positive virtual crossmatches and needlessly exclude recipients from organ allocation, and have questionable clinical significance after SOT.

As an extension of our work in identifying these antibodies, we questioned to what extent de novo DSA to donor antigens in the post-transplant period were due to recognition of nHLA
or β₂-m-fHLA. The present research compares conventional SAB analysis with acid treated (denatured) SAB to quantify the frequency of nHLA or β₂-m-fHLA, respectively among patients with de novo DSA after SOT. We also provide a small data set for the specificity for either clinical or histopathologic AMR among patients with positive DSA with nHLA or β₂-m-fHLA within a subset of these patients.

**Materials and methods**

This study was performed under the oversight of the Institutional Review Boards of Aurora Health Care and Avera McKennan Hospital and University System. Serum samples were collected from cardiac or renal transplant recipients who were at least 30 days post-transplant, and were obtained either under routine protocol surveillance or for cause as indicated by decline in cardiac or renal function. In cases where multiple post-transplant samples were available, we chose the sample that showed most recent to biopsy, otherwise, the sample with the highest mean fluorescence intensity (MFI) on SAB was chosen. All patients were negative for DSA by SAB assay (<500 MFI as defined below) and had negative flow cytometry crossmatches at the time of transplantation. Renal transplant recipients received basiliximab as induction therapy and were maintained on tacrolimus, mycophenolic mofetil (MMF), and steroids. Higher risk renal recipients (previous graft loss, high panel-reactive antibody (PRA), and African-American) were given thymoglobulin induction. Cardiac transplant recipients received bolus solumedrol at transplant followed by prednisone taper over an 11-week period along with MMF and tacrolimus maintenance immunotherapy. Histopathologic criteria for AMR were from the ISHLT Consensus Conference (16) and 2007 Banff (17) for heart and kidney grafts, respectively.

All samples were obtained from transplanted patients with positive DSA based on HLA class I SAB. Class II DSA were not considered for analysis because in our hands, acid and/or heat treatment denatures the antigens to the extent that are no longer reactive with human serum (data not shown). Our centers consider samples positive for DSA when MFI is ≥500 for any single bead or the sum of beads within more broad serological specificities. Although the cutoff was not validated clinically, it is consistent with the range of MFIs related to kidney allograft failure reported by the Collaborative Transplant Study Report of Opelz and colleagues (18). Samples with negative control beads >300 MFI were treated with Serum Cleaner [LifeCodes, Stamford, CT (#628222)] according to the manufacturer’s instructions and were spiked with fetal bovine serum (4% v/v) during incubation with beads. The HLA class I SAB arrays were purchased from Thermo-Fisher One Lambda (Canoga Park, CA) and used according to the manufacturer’s instructions. Data were obtained on a Lumines® 200 instrument and analyzed with FUSION (v 3.1) software. Reactivity to β₂-m-fHLA was determined by testing on beads that were denatured by low pH. Briefly, 2.5 µl of class I SAB beads were treated with 50 µl Pierce IgG Elution Buffer pH 2.4 (#21004, Rockford, IL) for 10 min on a rotator, and the reactions were neutralized by the addition of 5 µl 1 M Tris, pH 9. Denatured beads were washed with PBS containing 2% bovine serum albumin and then blocked in the same solution for 30 min at room temperature. The beads were pelleted by centrifugation then used according to the manufacturer’s instructions.

Antibodies were defined as reactive to β₂-m-fHLA when the MFI of acid-treated beads was ≥75% of the untreated bead MFI. Antibodies were defined as reactive to nHLA when the MFI of acid-treated beads was ≤40% of the untreated bead MFI. Antibodies were reported as mixed when the MFI of the acid-treated beads was between 40% and 75% of the untreated bead MFI, indicating reactivity with both β₂-m-fHLA and nHLA for the same antigen. Recipients with multiple DSA falling into more than one antibody category (β₂-m-fHLA, nHLA, or mixed HLA), were classified as multiple DSA. These were arbitrary assignments designed to provide a conservative estimate of the incidence of β₂-m-fHLA antibodies.

Selected samples from candidates for antibodies that were predominantly reactive with β₂-m-fHLA were tested by flow cytometry T- and B-cell crossmatch as previously described (9). Flow crossmatches were considered negative when channel shifts were ≤63 for T cells and ≤108 for B cells. These cutoffs represent three standard deviations from median channel fluorescence of a negative control serum validated for use in our clinical practice. Serum was considered positive for HLA class I only when supported by positive reactions for both T and B cells. In general, the flow crossmatch gives positive results on samples that provide 1000–2000 MFI on the SAB platform.

A one-way analysis of variance (ANOVA) test was used for comparison of differences in median values, and the chi-square or Fisher’s exact statistic was used for comparison of proportions. Statistics were run on SigmaStat software (Systat Software Inc., San Jose, CA) for Windows Version 11.0 and on http://vassarstats.net/fisher2x3.html.

**Results**

The HLA antigens that coat HLA class I single antigen Luminex® beads are a mixture of both native and β₂-microglobulin-free molecules. Figure 1 illustrates the staining of SAB with the mouse monoclonal antibodies W6/32 and HC-10 that recognize intact (β₂-microglobulin containing) and β₂-microglobulin-free class I HLA molecules, respectively. All class I HLA specificities represented on SAB are recognized by the W6/32 antibody, whereas only those alleles previously identified to contain the HC-10 epitope (19, 20) were reactive with the HC-10 antibody. SAB staining of acid-treated beads are completely nonreactive with W6/32 antibody to nHLA with the exception of a small amount of residual activity to a single bead carrying HLA-Cw12. These data confirm that acid elution of SAB completely converts nHLA to β₂-m-free forms. In addition, acid-treated beads show a complete absence of...
that none of the beads reached saturated MFI. Notice the near complete absence of the native HLA (W6/32 reactivity) on acid treated beads.

**Materials and methods**

Extensively, reacted with PE-labeled anti-mouse IgG [Jackson ImmunoResearch (West Grove, PA), 115-116-146] and then analyzed as described in the Methods and materials. Untreated beads were first reacted with 1 μg/ml monoclonal antibody to W6/32 (a gift of Dr Rico Buchli) or HC-10 (Nordic MUBio (Susteren, NL), MUB2037P), washed extensively, reacted with PE-labeled anti-mouse IgG [Jackson ImmunoResearch (West Grove, PA), 115-116-146] and then analyzed as described in the Methods and materials. Untreated beads were then stained with W6/32 monoclonal antibody; acid-treated beads stained with HC-10 monoclonal antibody. The histograms shown are from single concentrations (1 μg/ml) obtained from a dilution series of each antibody, and were selected to assure that none of the beads reached saturated MFI. Notice the near complete absence of the native HLA (W6/32 reactivity) on acid treated beads.

**Figure 1** Binding of HC-10 and W6/32 antibodies to untreated and acid-eluted human leukocyte antigen (HLA) class I single antigen bead (SAB). (A) W6/32 antibody (reactive with native HLA [nHLA]). (B) HC-10 antibody (reactive with β2-microglobulin-free HLA [β2-m-fHLA]). Untreated beads were first reacted with 1 μg/ml monoclonal antibody to W6/32 (a gift of Dr Rico Buchli) or HC-10 (Nordic MUBio (Susteren, NL), MUB2037P), washed extensively, reacted with PE-labeled anti-mouse IgG [Jackson ImmunoResearch (West Grove, PA), 115-116-146] and then analyzed as described in the Methods and materials. (C) Acid treated beads stained with W6/32 monoclonal antibody; (D) Acid-treated beads stained with HC-10 monoclonal antibody. The histograms shown are from single concentrations (1 μg/ml) obtained from a dilution series of each antibody, and were selected to assure that none of the beads reached saturated MFI. Notice the near complete absence of the native HLA (W6/32 reactivity) on acid treated beads.
Figure 2  Ratio of HC-10:W6/32 MFI on different human leukocyte antigen (HLA) specificities on single antigen bead (SAB). The histograms shown are from single concentrations (1 μg/ml) obtained from a dilution series of each antibody, and were selected to assure that none of the beads reached saturated MFI. MFI obtained are at near 50% maximal signal and represent the average of three independent experiments. Only specificities that are known to be reactive with HC-10 are shown.

Figure 3  Single antigen bead (SAB) histograms of a serum sample with reactivity to both native and β-2-microglobulin-free human leukocyte antigen (β2-m-fHLA) epitopes. (A) Serum tested on standard SAB. (B) Same serum sample run on denatured SAB. Circles (○) represent DSA; squares (◼) represent non-DSA.

© 2016 The Authors. HLA published by John Wiley & Sons Ltd.
staining with a monoclonal antibody to β₂-microglobulin (not shown) further validating the effectiveness of the denaturation procedure. Figure 2 shows estimates of each species obtained by a titration of each monoclonal antibody. The data clearly illustrate that for each antigen tested, β₂-m-fHLA is present at significant amounts, and in many cases is the predominant species of HLA molecule on SAB. When expressed as a ratio of MFI obtained at sub-saturating levels of antibodies, the majority of HLA antigens show greater reactivity with the antibody that recognizes the β₂-m-fHLA form. We obtained qualitatively similar data with Luminex® class I microarrays purchased from a different vendor (LifeCodes/Immucor; data not shown). Thus, our observations are more likely due to inherent properties of HLA class I antigens, and not related to a specific vendor's manufacturing process.

Having established that SAB contain both forms of HLA, serum samples from patients were tested on SAB under both standard and denaturing conditions. An example of data output obtained from a patient serum sample run under both standard and denatured conditions is shown in Figure 3. When run on SAB under standard conditions (Figure 3A), this serum shows antibody reactivity to DSA for HLA-A24 and HLA-B37, and non-DSA to HLA-A23, HLA-B44 and HLA-B45. Treatment of SAB with low pH (Figure 3B) resulted in a marked reduction in reactivity to HLA-A24, whereas reactivity to HLA-B37 was augmented. This reaction pattern confirms the presence of DSA to nHLA-A24 and β₂-m-fHLA-B37. The non-DSA in this example (HLA-A23, HLA-B44, and HLA-B45) all recognize nHLA as their reactivity is markedly diminished upon denaturation of SAB.

The distribution of patients identified with anti-nHLA and/or anti-β₂-m-fHLA is shown in Figure 4. Of the 55 patients tested, 29 had only anti-nHLA, 8 had only anti-β₂-m-fHLA, and the remaining 18 patients had mixed (both populations present) or multiple DSA. The frequency of antibodies exclusively to β₂-m-fHLA was similar among heart (17%) and renal (13%) allograft recipients. Table 1 shows the specificities of the DSA observed in the complete data set. The more common specificities of antibodies to β₂-m-fHLA included HLA-A1, HLA-B7, and HLA-B8, but there were no clear-cut associations between HLA antigens and whether or not the antibody reactivity was primarily reactive to β₂-m-fHLA or nHLA.

In order to further substantiate the reactivity of antibodies to β₂-m-fHLA and not nHLA, we performed flow cytometry crossmatches against viable lymphocytes from healthy volunteers (n = 11), which presumably express nHLA molecules as a majority. None of the antibodies interrogated yielded positive class I crossmatches (Table 2). The data substantiate that the antibodies identified as reactive to β₂-m-fHLA on denatured SAB are nonreactive with nHLA molecules. Selected β₂-m-fHLA antibodies (n = 8) were also tested for their ability to be blocked by pre-incubation of denatured beads with the HC-10 monoclonal antibody, which reacts with β₂-microglobulin-free heavy chains of many of the HLA-B and HLA-C gene products. In most cases (seven of eight), HC-10 completely blocked binding of the β₂-microglobulin-free antigens in question (data not shown), further supporting the specificity of these antibodies for β₂-m-fHLA.

Table 3 shows the breakdown of demographic and clinical data of patients with and without antibodies to β₂-m-fHLA. There were no statistically significant associations with age, sex, type of organ transplant, or objective function (ejection
### Table 1: Types of DSA in cardiac and renal transplant recipients

| Patient ID | Graft   | β2-m-fHLA specificity | nHLA specificity | Mixed HLA specificity |
|------------|---------|-----------------------|------------------|----------------------|
| 1          | Heart   | None                  | A68 (592)        | None                 |
| 2          | Heart   | None                  | B44 (1951)       | None                 |
| 3          | Heart   | B8 (514)              | None             | None                 |
| 4          | Heart   | B37 (2345)            | A24 (4900)       | B8 (620)             |
| 5          | Heart   | None                  | A3 (3844), A11 (7170) | B27 (11,832) |
| 6          | Kidney  | None                  | A2 (15,580)      | A36 (8496)           |
| 7          | Heart   | None                  | B57 (1601)       | B7 (11,005)          |
| 8          | Heart   | None                  | A3 (1941), B62 (1246) | A1 (3630) |
| 9          | Kidney  | None                  | A2 (961)         | None                 |
| 10         | Kidney  | None                  | None             | A11 (4328), B8 (3237) |
| 11         | Heart   | None                  | A11 (3475), A24 (4748) | None     |
| 12         | Heart   | None                  | A2 (7682), A30 (1945), B13 (1570), B50 (1888) | None |
| 13         | Heart   | None                  | B45 (650)        | A34 (13,479)         |
| 14         | Heart   | None                  | A24 (2581)       | None                 |
| 15         | Heart   | None                  | A24 (3666)       | None                 |
| 16         | Heart   | B55 (910)             | None             | None                 |
| 17         | Heart   | A11 (1488)            | None             | None                 |
| 18         | Heart   | None                  | A1 (593), A31 (712), B8 (1960), B27 (1115) | None |
| 19         | Kidney  | None                  | A1 (7370), A32 (3240), B57 (3949) | None |
| 20         | Kidney  | B72 (1230)            | None             | None                 |
| 21         | Kidney  | None                  | A11 (1062)       | None                 |
| 22         | Heart   | None                  | B53 (529), B57 (2747) | None     |
| 23         | Heart   | B8 (1138)             | A1 (5199), A25 (1424), B18 (832) | None |
| 24         | Kidney  | None                  | B51 (7872), B60 (6240) | None     |
| 25         | Kidney  | None                  | A2 (19,623), A32 (735), B8 (4352) | None |
| 26         | Kidney  | None                  | A1 (1266)        | None                 |
| 27         | Kidney  | None                  | B49 (12,165)     | None                 |
| 28         | Kidney  | A31 (950)             | B60 (2564)       | None                 |
| 29         | Kidney  | None                  | A2 (9673)        | A24 (2618)           |
| 30         | Kidney  | None                  | Cw17 (3316)      | None                 |
| 31         | Kidney  | None                  | A11 (865), B51 (2725), Cw15 (8386) | None |
| 32         | Kidney  | None                  | A29 (566), B44 (2460) | None     |
| 33         | Kidney  | A1 (940)              | None             | None                 |
| 34         | Kidney  | None                  | A1 (2577), A2 (1111) | None     |
| 35         | Kidney  | None                  | A26 (5753)       | None                 |
| 36         | Kidney  | None                  | B27 (6154), Cw1 (1077) | None |
| 37         | Kidney  | None                  | Cw10 (3702)      | None                 |
| 38         | Kidney  | None                  | None             | A24 (2056)           |
| 39         | Kidney  | None                  | A2 (1595)        | None                 |
| 40         | Kidney  | None                  | A68 (2586), A69 (1048), B60 (1152) | None |
| 41         | Kidney  | A24 (510)             | Cw4 (1051)       | None                 |
| 42         | Kidney  | B44 (863)             | None             | None                 |
| 43         | Kidney  | None                  | A2 (3294), B51 (3330) | Cw15 (1001) |
| 44         | Kidney  | A1 (652)              | None             | A24 (963), B61 (739) |
| 45         | Kidney  | None                  | A2 (6007), A23 (8922), B49 (1012), B51 (1987) | None |
| 46         | Kidney  | None                  | None             | A2 (1953), B7 (639) |
| 47         | Kidney  | None                  | A2 (1270), B44 (1764) | None     |
| 48         | Kidney  | None                  | A2 (3333), B50 (1436) | None     |
| 49         | Kidney  | None                  | A31 (1546), B58 (811) | None     |
| 50         | Kidney  | None                  | None             | A33 (1418)           |
| 51         | Kidney  | None                  | B51 (904)        | B44 (3165)           |
| 52         | Kidney  | None                  | B7 (3983)        | None                 |
| 53         | Kidney  | None                  | A2 (29,694)      | None                 |
| 54         | Kidney  | None                  | Cw6 (1982), Cw7 (1477) | A1 (601) |
| 55         | Heart   | None                  | A2 (7894)        | B60 (992)            |

**Notes:**
- DSA, donor-specific antibody; β2-m-fHLA, β2-microglobulin-free human leukocyte antigen; nHLA, native human leukocyte antigen; ND, not determined.
- MFI of specific bead, or the sum of beads within more broad serological specificities, observed during standard SAB assay is shown in parentheses for each antibody identified.
- β2-m-fHLA specificity, antibody target identified as β2-m-free HLA.
- nHLA specificity, antibody target identified as native HLA.
- Mixed HLA specificity, antibody target identified as both native HLA and β2-m-free HLA.
Among the AMR negative group, 4 of 22 (18%) patients had β 2-m-fHLA. There was considerable overlap between the two groups. In addition, antibodies to β 2-m-fHLA were of lower mean and median fluorescence intensity in standard SAB assays than those that recognize nHLA specificities; however, there was considerable overlap between the two groups. Table 6 compares the fluorescence characteristics of each group. Table 6 compares the fluorescence intensity values obtained for antibodies to nHLA and the β 2-m-fHLA on both denatured vs conventional SAB. As a group, antibodies to β 2-m-fHLA are of lower mean and median fluorescence intensity in standard SAB assays than those that recognize nHLA specificities; however, there was considerable overlap between the two groups. In addition, antibodies to β 2-m-fHLA tended to produce higher MFI on denatured SAB than those observed on standard SAB, presumably due to conversion of all HLA antigens to the β 2-m-fHLA species upon denaturation.

### Discussion

This study provides several observations regarding the development of antibodies to HLA following SOT. First, the antibodies that are reactive to β 2-m-fHLA class I antigens are a common finding, as they were observed in 43% and 56% of patients with

#### Table 2: Surrogate crossmatching of sera reactive to β 2-m-fHLA

| Patient ID | DSA identified to β 2-m-fHLA | MFI on nHLA, β 2-m-fHLA | MFI on conventional SAB | T cell MDCSa | B cell MDCSb | Crossmatch resultc |
|------------|-------------------------------|-------------------------|-------------------------|--------------|--------------|-------------------|
| 3          | B8                            | 514                     | <1                      | 56           | Negative     |
| 20         | B55                           | 910                     | <1                      | Negative     |
| 21         | A11                           | 1468                    | 17                      | Negative     |
| 35         | A31                           | 960                     | 79                      | Negative     |
| 41         | A1                            | 940                     | 196                     | Negative     |
| 49         | A24                           | 510                     | 100                     | Negative     |
| 50         | B44                           | 883                     | <1                      | Negative     |
| 52         | A1                            | 65                      | <1                      | Negative     |
| 54         | A2                            | 1963                    | 132                     | Negative     |
| 54         | B7                            | 639                     | 50                      | Negative     |
| 62         | B7                            | 3983                    | <1                      | Negative     |

β 2-m-fHLA, β2-microglobulin-free human leukocyte antigen; MDCS, median channel shift.

aMFI of specific bead, or the sum of beads within more broad serological specificities.

bData expressed as MDCS relative to negative control serum, and the value reflects the mean of duplicate assays.

cNegative result indicates MDCS ≤63 for T cells and ≤108 for B cells.

#### Table 3: Demographic and clinical data of patients with DSA to β 2-m-fHLA vs native HLA.

| Number of recipients | β 2-m-fHLA recipients | Mixed/multiple HLA recipients | P-value |
|----------------------|------------------------|-------------------------------|---------|
| Gender               | 29                     | 8                             | 18      |
| Age at time of sample| 28                     | 8                             | 17      |
| Number of known age  | 29                     | 8                             | 18      |
| Median               | 53                     | 45                            | 53      |
| A/B/DR mismatches    | 29                     | 8                             | 18      |
| Median               | 5                      | 5                             | 5       |
| Ejection fraction    | 8                      | 3                             | 7       |
| Median               | 63%                    | 62%                           | 55%     |
| Creatinine level     | 16                     | 3                             | 8       |
| Median               | 2.4 mg/dl              | 2.0 mg/dl                     | 2.2 mg/dl|

DSA, donor-specific antibody; β 2-m-fHLA, β2-microglobulin-free human leukocyte antigen; NS, not significant.

#### Table 4: Incidence of histopathologic diagnosis of AMR among recipients expressing DSA to β 2-m-fHLA, native HLA, or multiple HLA.

| Number of recipients | β 2-m-fHLA recipients | Multiple HLA recipients | P-value |
|----------------------|------------------------|-------------------------|---------|
| AMR−                 | 13                     | 4                       | 5       |
| AMR+                 | 3                      | 0                       | 4       |

DSA, donor-specific antibody; β 2-m-fHLA, β2-microglobulin-free human leukocyte antigen.

**P-value** determined using Fisher’s exact test.

De novo DSA to HLA

© 2016 The Authors. HLA published by John Wiley & Sons Ltd.

HLA, 2016, 87, 356–366
DSAs, donor-specific antibody; β₂-m-fHLA, β2-microglobulin-free human leukocyte antigen.

**Table 5** Frequency of DSA and non-DSA, directed to native, β₂-m-fHLA, or mixed HLA

|                | nHLA | β₂-m-fHLA | Mixed HLA |
|----------------|------|-----------|-----------|
| DSA            | 72%  | 13%       | 15%       |
| Non-DSA        | 71%  | 18%       | 11%       |

DSA, donor-specific antibody; β₂-m-fHLA, β2-microglobulin-free human leukocyte antigen.

**Table 6** Fluorescence characteristics of DSA observed on standard and acid-treated SAB

|                | MFI measured on standard SAB | MFI measured on acid-treated SAB |
|----------------|------------------------------|----------------------------------|
|                | nHLA | β₂-m-fHLA | Mixed HLA | nHLA | β₂-m-fHLA | Mixed HLA |
| N               | 76   | 14        | 16        | 76   | 14        | 16        |
| Average         | 4018 | 1292      | 3544      | 395  | 2690      | 1954      |
| Median          | 2507 | 945       | 2337      | 96   | 1807      | 1264      |
| Range           | 529–29,694 | 510–3982 | 601–11,832 | 0–5852 | 591–11,952 | 352–6202 |

DSA, donor-specific antibody; β₂-m-fHLA, β2-microglobulin-free human leukocyte antigen; nHLA, native HLA; SAB, single antigen bead.

© 2016 The Authors. HLA published by John Wiley & Sons Ltd.
HLA, 2016, 87, 356–366
donors described unexplained and undefined reactivities to relatively rare HLA alleles (4). The data presented here and in several other publications (9, 10, 38) document that these reactions are not limited to rare HLA specificities, but in fact are frequent among common HLA alleles. While our finding of antibodies to $\beta_2$-m-fHLA in the post-transplant period are perhaps not surprising, prior publications on the topic of antibodies to denatured HLA have evaluated specimens obtained in the pre-transplant period (9, 10, 12–15, 38). Thus, our work is consistent with prior reports and extends them into the post-transplant clinical setting. An obvious extension of our work would be to perform serial studies on the development of antibodies to $\beta_2$-m-fHLA in the post-transplant period and examine their relationship to the development of AMR.

A plausible mechanism for the production of antibodies to $\beta_2$-m-fHLA stems from early observations of the structure of class I HLA; these proteins can be arranged on cells in at least two forms. First is the classical heterodimer of the heavy chain in association with $\beta_2$-microglobulin that is recognized by conformation-dependent antibodies such as W6/32 (39), and second are $\beta_2$-microglobulin-free class I alpha chains recognized by antibodies such as HC-10 (19) and LA45 (40). The latter were first described by Schnabl et al. (41) in activated human T cells, and their expression was shown to require internalization via the endosome compartment (42, 43). Thus, $\beta_2$-microglobulin-free class I heavy chains appear to be generated during the process of class I heterodimer recycling. Because manufacturing of SAB involves covalent conjugation of class I antigens en masse, it likely leads to loading of a mixture of classical heterodimer and $\beta_2$-microglobulin-free forms of heavy chain in proportion to the content of each species that were expressed on the cells from which the antigens were extracted.

As $\beta_2$-microglobulin-free class I molecules represent natural alternative forms of alloantigen, we speculate that the ‘cryptic’ epitopes that arise from conformational changes in the heavy chains provide immunogenic stimuli to distinct populations of B cells in ways similar to conventional intact class I molecules. Our finding that many DSA represent a mixture of antibodies to both nHLA and $\beta_2$-m-fHLA is supportive of the aforementioned concept. Given that some samples contained only one population of HLA molecules (nHLA or $\beta_2$-m-fHLA) might also suggest different mechanisms of immune activation. For example, the predominance of the $\beta_2$-m-fHLA form might be expected to arise under natural conditions of cell degradation from processes of apoptosis and/or necrosis, as both processes involve acidic and proteolytic microenvironments of the endocytic and phagocytic pathways (44). It is also possible that soluble forms of HLA found in blood plasma (45) contain a greater proportion of $\beta_2$-m-fHLA, thus supplying novel epitopes to antigen presenting cells. It is also feasible that antibodies to HLA proteins could recognize linear epitopes within the HLA molecule. As such, these antibodies could recognize both nHLA and/or $\beta_2$-m-fHLA. These antibodies would, of course account for the observation of specificities identified as ‘mixed’. Although not the focus of this study, we have performed a preliminary series of experiments with sera that recognize $\beta_2$-m-fHLA of HLA-A2 tested against overlapping 30-mer linear peptides of the A2 molecule and where unable to detect any reactivity in an enzyme-linked immunosorbent assay (ELISA) format (unpublished data). If further studies of other HLA specificities hold true, this would suggest that the epitopes recognized by antibodies to $\beta_2$-m-fHLA are discontinuous. Thus, alloimmunization to these forms would likely be due to antigen presentation of intact heavy chains, not simply degradation products thereof.

The identification of antibodies to $\beta_2$-m-fHLA might be of practical importance as patient samples with DSA exclusive to $\beta_2$-m-fHLA type had no clinical or histologic evidence of AMR. Additionally, sole reliance of current SAB testing platforms to assist in the diagnosis of AMR without consideration of whether the DSA recognize nHLA or $\beta_2$-m-fHLA could confound the diagnosis of AMR. Both of these implications will need to be validated and reproduced in larger sets of SOT patients with and without AMR. Nonetheless, our observation of a lack of AMR in patients with DSA exclusively to $\beta_2$-m-fHLA is consistent with observations of the lack of clinical importance of pre-formed antibodies to $\beta_2$-m-fHLA at the time of transplant (10, 12–15). If our findings are validated and extended by other labs and it holds true that antibodies to $\beta_2$-m-fHLA have no clinical relevance, we think it would prove appropriate to perform similar acid elution studies on all patients to rule out false positive SAB. Our findings also illustrate the need for manufacturers to develop platforms that consist only of native forms of HLA, or in the absence of that, provide users information regarding the relative amounts of intact vs. $\beta_2$-m-fHLA.

In summary, while the SAB antibody detection platforms are highly sensitive and represent a dramatic improvement in the detection of antibodies to HLA, an unintended consequence of their use is the identification of antibodies that lack specificity for nHLA antigens. Our data add to previous observations that pre-transplant antibodies to $\beta_2$-m-fHLA are not a barrier to organ transplantation and support the concept that DSA to $\beta_2$-m-fHLA does not appear to confer a pathologic role in the development of clinical or histologic AMR. The rapid adoption of these SAB platforms has already led to changes in clinical management of waiting lists for SOT, and their use in post-transplant monitoring is widespread. The data presented here raise concerns about the specificity of DSA testing and highlight the need for a reassessment of the clinical relevance of many HLA antibodies in the diagnosis and management of AMR.

Acknowledgments

The authors gratefully acknowledge the assistance of the staffs of the ACL and the Avera McKennan HLA Laboratories, and the volunteer blood donors for flow crossmatching. We also
thank Dr Rico Buchli of Pure Protein for the gift of the W6/32 monoclonal antibody and helpful discussions during the course of this work. Finally, we acknowledge the contributions of the Aurora and Avera McKennan physicians and transplant group support staff for clinical care of our transplant patients.

This work was supported by a grant (#570-3970) from the Department of Cardiovascular Surgery at Aurora St. Luke’s Medical Center, Milwaukee, WI.

KM performed experiments, data analysis and drafted the article. RS, JS, AS, and FXD studied concept and reviewed/edited manuscript. VT studied concept, reviewed/edited article. RS, JS, AS, and FXD studied concept and reviewed/edited articles, data analysis, wrote manuscript, and secured funding. MO studied concept and designed experiments, data analysis, wrote manuscript, and secured funding.

Conflict of interests
The authors have declared no conflicting interests.

References
The authors have declared no competing interests.

1. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011: 30: 252–69.
2. Tait BD, Susal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013: 95: 19–47.
3. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003: 75: 43–9.
4. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008: 86: 1111–5.
5. El-Awar N, Terasaki PI, Nguyen A et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009: 70: 844–53.
6. Pereira S, Perkins S, Lee JH et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol 2011: 72: 492–8.
7. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008: 20: 602–6.
8. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009: 88: 226–30.
9. Oaks M, Michel K, Sulemanjee NZ, Thohan V, Downey FX. Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. J Heart Lung Transplant 2014: 33: 713–720.
10. Visentin J, Guidicelli G, Bachelet T et al. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation 2014: 98: 738–44.
11. Tait BD. Antibodies to denatured human leukocyte antigen: relevant or just noise? Transplantation 2014: 98: 695–6.
12. Poli F, Benazzi E, Innocente A et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report. Hum Immunol 2011: 72: 1045–8.
13. Jacob EK, De Goey SR, Gandhi MJ. Positive virtual crossmatch with negative flow crossmatch results in two cases. Transpl Immunol 2011: 25: 77–81.
14. Nikaein A, El-Awar N, Hunt J et al. Clinically irrelevant circulating human leukocyte antigen antibodies in the presence of ventricular assist devices. J Heart Lung Transplant 2012: 31: 443–7.
15. Visentin J, Marroc M, Guidicelli G et al. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clin Transplant 2015: 29: 393–402.
16. Berry GJ, Burke MM, Andersen C et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013: 32: 1147–62.
17. Solec K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008: 8: 753–60.
18. Susal C, Wettstein D, Dolher B et al. Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing. Transplantation 2015: 99: 1976–80.
19. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986: 137: 2299–306.
20. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Damaccio F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003: 171: 1918–26.
21. Gupta G, Abu Jawdeh BG, Racusen LC et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation 2014: 97: 1240–6.
22. Haas M, Iss B, Racusen LC et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014: 14: 272–83.
23. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol 2012: 73: 1213–7.
24. Yamakuchi M, Kikilises-Smith NC, Ferlito M et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A 2007: 104: 1301–6.
25. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol 2013: 190: 6635–50.
26. Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection. Trends Mol Med 2015: 21: 319–29.
27. Kaneku H. Annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 2013: 2013: 63–75.

28. Everly MJ, Rebellato LM, Haisch CE et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013: 95: 410–7.

29. Wiebe C, Gibson JW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012: 12: 1157–67.

30. Torres IB, Salcedo M, Moreso F et al. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Clin Transplant 2014: 28: 1148–54.

31. Frank R, Molina MR, Goldberg LR, Wald JW, Kamoun M, Lal P. Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. Am J Clin Pathol 2014: 142: 809–15.

32. Halloran PF, Chang J, Famulski K et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2015: 26: 1711–20.

33. Tait BD, Hudson F, Cantwell L et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009: 14: 247–54.

34. Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R. Solid phase HLA antibody detection technology – challenges in interpretation. Tissue Antigens 2010: 76: 87–95.

35. Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant 2014: 14: 1964–75.

36. Hoshino J, Kaneku H, Everly MJ, Greenwood S, Terasaki PI. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012: 93: 1173–8.